Epilepsy and Brain Health: Rafal Kaminski advocates Global Action and Unity
Neurological disorders affect 43.1% of the global population[1]. In this regard, epilepsy continues to be among top 10 most impactful neurological disorders[1], with a prevalence that affects up to 1 person out of 100 worldwide[2]. The implications of this condition are broad and varied, limiting individuals' ability to work, drive and participate in daily activities. It is a challenge that requires attention both from institutions and companies, each contributing in their own field.
Rafal Kaminski, Chief Scientific Officer of Angelini Pharma, discusses this in depth in an article published in Pharmafocus. Rafal not only analyzes the regulatory landscape, but also highlights Angelini Pharma's significant commitment to Brain Health.
In 2023, the Intersectoral Global Action Plan (IGAP) for epilepsy and other neurological disorders was published, with the aim of improving access to new treatments, quality of life, and raise awareness to tackle stigma[3]. Angelini Pharma actively collaborates with WHO and other international health bodies to put this plan into action, prioritizing the development of cutting-edge therapies, enhancing regulatory frameworks, and driving change through coordinated efforts globally.
In this context, the "Headway" initiative emerges, promoted by The European House Ambrosetti in partnership with Angelini Pharma. This project aims to create a multidisciplinary platform for strategic reflection, analysis, dialogue and comparison between various European experiences in the management of people with mental and neurological disorders.
This concrete commitment by Angelini Pharma not only aims to improve therapies and patients' lives but also demonstrates social responsibility and an active role in building a more inclusive and aware society of the issues related to mental and neurological health.
[1] Global brain health – the time to act is now. Lancet Global Health 2024. March 14,2024. Available at: https://www.thelancet.com/pdfs/journals/langlo/PIIS2214-109X(23)00602-2.pdf
[2] Coste, J., Mandereau-Bruno, L., Carcaillon-Bentata, L. et al. Prevalence, demographic and spatial distribution of treated epilepsy in France in 2020: a study based on the French national health data system. J Neurol 271, 519–525 (2024). https://doi.org/10.1007/s00415-023-11953-2.
[3] Global brain health – the time to act is now. Lancet Global Health 2024. March 14,2024. Available at: https://www.thelancet.com/pdfs/journals/langlo/PIIS2214-109X(23)00602-2.pdf